Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work
Big name partnerships were critical for Nimbus Therapeutics’ first decade. With a head-turning $1.2 billion — $600 million of which were paid within months — deal from Gilead and a returning customer in Celgene, the biotech emerged as a prolific pioneer of computational chemistry and structure-based drug discovery while the industry went through a seismic shift in its thinking of the role that algorithms play in engineering new therapies.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters